Baseline characteristics and treatment patterns in HFpEF/HFmrEF patients on dapagliflozin: final analysis of baseline data from the two EVOLUTION-HF DEallEF study cohorts

M. Paul (Münster)¹, A. Guth (Frankenthal)², B. Subin (Hamburg)³, R. Bosch (Ludwigsburg)⁴, C. Zugck (Straubing)⁵, J. Langel (Gera)⁶, W. Richter (Essen)⁷, J. Taggeselle (Markkleeberg)⁸, M. Knapp (Schwäbisch Hall)⁹, S. H. Schirmer (Kaiserslautern)¹⁰, D. Weinrich (Berlin)¹¹, C. Axthelm (Pirna)¹², M. Klutmann (Aachen)¹³, F. Rödicker (Hamurg)¹⁴, B. Aßmus (Gießen)^15
1Kardiologie Praxis Münster Münster, Deutschland; ²Promedi-Kardiologie Frankenthal, Deutschland; ³CardioMed an der Alster Kardiologisch-Internistische Gemeinschaftspraxis Hamburg, Deutschland; ⁴Cardio Centrum Ludwigsburg Bietigheim Ludwigsburg, Deutschland; ⁵Praxis im Steiner Thor Straubing, Deutschland; ⁶Kardiologische Praxis Gera Gera, Deutschland; ⁷Dr. Richter & Kollegen Essen, Deutschland; ⁸Kardiologische Praxis Markkleeberg, Deutschland; ⁹Facharztpraxis für Kardiologie und Innere Medizin Schwäbisch Hall, Deutschland; ¹⁰Kardiopraxis Schirmer‍ Kaiserslautern, Deutschland; ¹¹MVZ Drs. Weinrich GmbH Berlin, Deutschland; ¹²Cardiologicum Dresden und Pirna Pirna, Deutschland; ¹³Praxis für Kardiologie Aachen Aachen, Deutschland; ¹⁴AstraZeneca GmbH Medical Department, BioPharmaceuticals Medical Hamurg, Deutschland; ¹⁵Universitätsklinikum Gießen und Marburg GmbH Medizinische Klinik I - Kardiologie und Angiologie Gießen, Deutschland

Background
Heart failure (HF) is one of the world’s leading public health issues. Standard HF treatment combines different drug classes depending on the underlying cause of HF and ejection fraction (EF). The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin is approved in Germany for the treatment of heart failure independently of EF. As real-world data are limited, the EVOLUTION-HF DE_allEF study (NCT06336330) currently investigates patients’ characteristics, treatment patterns, and real-world use of dapagliflozin in Germany.

Methods
EVOLUTION-HF DE_allEF is a non-interventional, prospective, longitudinal cohort study, planned to enroll 1.000 patients with chronic HF in Germany [400 with preserved (HFpEF; EF ≥50%), 200 with mildly reduced (HFmrEF; EF 41-49%), and 400 with reduced EF (HFrEF; EF ≤40%)]. It includes patients aged ≥18 years, who started dapagliflozin for HF according to local product label within 14-90 days prior to enrollment. Exclusion criteria comprise prior SGLT2i therapy and type 1 diabetes. Data on medical history, clinical symptoms, previous and concomitant medication, HF/diabetes treatment patterns, utilization of health care resources and patient-reported outcomes are collected. The first patient was enrolled in April 2024. Enrollment for the HFpEF and HFmrEF cohorts was completed in October 2025 and is still open for patients with HFrEF.

Results
This presentation will report the complete baseline data for the HFpEF and HFmrEF cohorts (data cutoff: NOV 2025). Findings will cover demographic and clinical characteristics, pre-treatment information, current therapy patterns, and safety data. Descriptive statistical methods will be used.

Conclusion
EVOLUTION-HF DE_allEF provides real-world insight into dapagliflozin use for heart failure in Germany, focusing on clinical profiles and patient-reported outcomes. The study’s results are anticipated to inform about actual clinical practice and may help to guide future research in patients with different HF phenotypes.